Germany’s coronavirus vaccination campaign faced delays in several cities on Sunday after temperature trackers showed that about 1,000 of the shots made by BioNTech and Pfizer may not have been kept cold enough during transit, APA reports citing Reuters.
“When reading the temperature loggers that were enclosed in the cool boxes, doubts arose about the compliance with the cold chain requirements,” the district of Lichtenfels in the north of Germany’s largest state Bavaria said in a statement.
Medical staff found that the temperature in one vaccine transport cool box had risen to 15 degrees Celsius, a spokesman for Lichtenfels said, above the maximum of 8C stipulated by the manufacturers.
BioNTech was not immediately available for comment. Pfizer referred Reuters to its German partner for comment on the issue.
The vaccine, which uses new so-called mRNA technology, must be stored at ultra-low temperatures of about -70 degrees Celsius (-112°F) before being shipped to distribution centers in specially designed cool boxes filled with dry ice.
Once out of ultra-low temperature storage, the vaccine must be kept at 2C to 8C to remain effective for up to five days. The cool boxes designed by Pfizer are fitted with GPS trackers so the companies can deal with potential storage issues en route.
The spokesman for Lichtenfels said 1,000 shots had been affected by the temperature issue and that the city and the districts of Coburg, Kronach, Kulmbach, Hof, Bayreuth and Wunsiedel in northern Bavaria were waiting to hear from BioNTech about whether the vaccine could still be used.
“Vaccination against the coronavirus is not about who vaccinates the fastest or who does the most doses. Safety and conscientious work for the benefit of the population has the highest priority,” said Oliver Baer, district administrator in Hof.
The European Union launched a mass COVID-19 vaccination drive on Sunday with pensioners and medics lining up to get the first shots to see off a pandemic that has crippled economies and claimed more than 1.7 million lives worldwide.
The delays in Germany highlight the challenge in rolling out the vaccine while regulators review for approval other shots, including those made by Moderna and AstraZeneca, which are easier to transport and store.